These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 20352562)

  • 21. Bone mineral density in women using depot medroxyprogesterone acetate (DMPA) for at least 2 years compared to a control group: a cross sectional study.
    Pongsatha S; Ekmahachai M; Chaovisitsaree S; Suntornlimsiri N; Morakote N
    J Med Assoc Thai; 2009 Oct; 92(10):1263-7. PubMed ID: 19845231
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-acting hormonal contraception: assessing impact on bone density, weight, and mood.
    Kaunitz AM
    Int J Fertil Womens Med; 1999; 44(2):110-7. PubMed ID: 10338269
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of the long-term use of depot medroxyprogesterone acetate as hormonal contraceptive on bone mineral density and biochemical markers of bone remodeling.
    Shaarawy M; El-Mallah SY; Seoudi S; Hassan M; Mohsen IA
    Contraception; 2006 Oct; 74(4):297-302. PubMed ID: 16982229
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Merits of DMPA relative to other reversible contraceptive methods.
    Nelson A
    J Reprod Med; 2002 Sep; 47(9 Suppl):781-4. PubMed ID: 12380406
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Depot medroxyprogesterone acetate contraception. Metabolic parameters and mood changes.
    Westhoff C
    J Reprod Med; 1996 May; 41(5 Suppl):401-6. PubMed ID: 8725702
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Depot medroxyprogesterone acetate: implications for weight status and bone mineral density in the adolescent female.
    Bonny AE; Harkness LS; Cromer BA
    Adolesc Med Clin; 2005 Oct; 16(3):569-84. PubMed ID: 16183540
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early experience with the contraceptive use of depot medroxyprogesterone acetate in an inner-city clinic population.
    Polaneczky M; Guarnaccia M; Alon J; Wiley J
    Fam Plann Perspect; 1996; 28(4):174-8. PubMed ID: 8853283
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bone mineral density in women aged 40-49 years using depot-medroxyprogesterone acetate, norethisterone enanthate or combined oral contraceptives for contraception.
    Beksinska ME; Smit JA; Kleinschmidt I; Farley TM; Mbatha F
    Contraception; 2005 Mar; 71(3):170-5. PubMed ID: 15722065
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Depot medroxyprogesterone acetate use after peak bone mass is associated with increased bone turnover but no decrease in bone mineral density.
    Walsh JS; Eastell R; Peel NF
    Fertil Steril; 2010 Feb; 93(3):697-701. PubMed ID: 19013564
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized controlled trial of estrogen replacement therapy in long-term users of depot medroxyprogesterone acetate.
    Cundy T; Ames R; Horne A; Clearwater J; Roberts H; Gamble G; Reid IR
    J Clin Endocrinol Metab; 2003 Jan; 88(1):78-81. PubMed ID: 12519833
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Injectable contraception.
    Mishell DR
    J Reprod Med; 2002 Sep; 47(9 Suppl):777-9. PubMed ID: 12380405
    [No Abstract]   [Full Text] [Related]  

  • 32. Bone density recovery after depot medroxyprogesterone acetate injectable contraception use.
    Kaunitz AM; Arias R; McClung M
    Contraception; 2008 Feb; 77(2):67-76. PubMed ID: 18226668
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The association between depot medroxyprogesterone acetate contraception and bone mineral density in adolescent women.
    Scholes D; LaCroix AZ; Ichikawa LE; Barlow WE; Ott SM
    Contraception; 2004 Feb; 69(2):99-104. PubMed ID: 14759613
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bone mineral density testing, and bisphosphonate and oestrogen prescribing associated with depot medroxyprogesterone acetate utilization-The impact of the boxed warning.
    Eworuke E; Popat V; Moeny DG
    J Clin Pharm Ther; 2017 Aug; 42(4):483-494. PubMed ID: 28543135
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of depot medroxyprogesterone acetate (DMPA) on bone mineral density (BMD) and evaluating changes in BMD after discontinuation of DMPA in Chinese women of reproductive age.
    Gai L; Zhang J; Zhang H; Gai P; Zhou L; Liu Y
    Contraception; 2011 Mar; 83(3):218-22. PubMed ID: 21310282
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current concepts regarding use of DMPA.
    Kaunitz AM
    J Reprod Med; 2002 Sep; 47(9 Suppl):785-9. PubMed ID: 12380407
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-acting injectable contraception with depot medroxyprogesterone acetate.
    Kaunitz AM
    Am J Obstet Gynecol; 1994 May; 170(5 Pt 2):1543-9. PubMed ID: 8178904
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain.
    Schlaff WD; Carson SA; Luciano A; Ross D; Bergqvist A
    Fertil Steril; 2006 Feb; 85(2):314-25. PubMed ID: 16595206
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of depot medroxyprogesterone acetate contraception in adolescents.
    Davis AJ
    J Reprod Med; 1996 May; 41(5 Suppl):407-13. PubMed ID: 8725703
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Depot medroxyprogesterone acetate contraception in women with medical problems.
    Frederiksen MC
    J Reprod Med; 1996 May; 41(5 Suppl):414-8. PubMed ID: 8725704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.